Gambaran Umum
Bolt Biotherapeutics, Inc., based in the United States, operates within the biotechnology sector, focusing on the development of immuno-oncology treatments. The company’s innovative approach leverages its proprietary Boltbody™ platform which harnesses the power of the immune system to fight cancer by targeting tumor cells and promoting anti-tumor responses. Key projects include a range of investigational drugs designed to enhance the efficacy of immune-stimulating antibodies against various oncologic indications. Among its notable developments is BDC-1001, a lead clinical candidate targeting HER2-expressing tumors, reflecting the company’s commitment to advancing novel therapeutics into clinical settings to address significant unmet medical needs in oncology. Bolt Biotherapeutics is strategically positioned to potentially transform cancer treatment paradigms, aligning with its focus on pioneering advancements in biotherapeutics.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Bolt Biotherapeutics, Inc. per 2025 Jun 30 adalah 4.17 MM.
- Nilai operating income untuk Bolt Biotherapeutics, Inc. per 2025 Jun 30 adalah -53.44 MM.
- Nilai net income untuk Bolt Biotherapeutics, Inc. per 2025 Jun 30 adalah -50.71 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 4.17 | -53.44 | -50.71 |
2025-03-31 | 3.64 | -63.26 | -63.35 |
2024-12-31 | 7.69 | -68.24 | -63.12 |
2024-09-30 | 9.78 | -72.33 | -65.08 |
2024-06-30 | 11.17 | -74.07 | -66.17 |
2024-03-31 | 11.32 | -74.87 | -63.03 |
2023-12-31 | 7.88 | -76.20 | -69.20 |
2023-09-30 | 7.20 | -77.47 | -71.29 |
2023-06-30 | 6.78 | -81.63 | -76.79 |
2023-03-31 | 6.74 | -84.86 | -81.40 |
2022-12-31 | 5.73 | -90.32 | -88.10 |
2022-09-30 | 4.83 | -96.36 | -95.26 |
2022-06-30 | 3.47 | -97.54 | -96.89 |
2022-03-31 | 2.07 | -98.24 | -97.81 |
2021-12-31 | 1.26 | -92.79 | -98.59 |
2021-09-30 | 0.75 | -82.64 | -102.47 |
2021-06-30 | 0.00 | -71.51 | -89.08 |
2021-03-31 | 0.07 | -58.86 | -76.55 |
2020-12-31 | 0.23 | -49.18 | -60.73 |
2020-09-30 | 0.30 | -41.77 | -39.05 |
2020-06-30 | |||
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -1.71 | -1.71 |
2024-06-30 | -1.74 | -1.74 |
2024-03-31 | -1.66 | -1.66 |
2023-12-31 | -1.83 | |
2023-09-30 | -1.89 | -1.89 |
2023-06-30 | -2.04 | -2.04 |
2023-03-31 | -2.17 | -2.17 |
2022-12-31 | -2.36 | |
2022-09-30 | -2.55 | -2.55 |
2022-06-30 | -2.60 | -2.60 |
2022-03-31 | -2.64 | -2.64 |
2021-12-31 | -2.97 | |
2021-09-30 | -4.20 | -4.20 |
2021-06-30 | -5.71 | -5.71 |
2021-03-31 | -11.00 | -11.00 |
2020-12-31 | -28.89 | |
2020-09-30 | -18.74 | -18.74 |
2020-06-30 | -17.56 | -17.56 |
2020-03-31 | -15.86 | -15.86 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Bolt Biotherapeutics, Inc. per 2025 Jun 30 adalah -51.36 MM.
- Nilai cash from investing activities untuk Bolt Biotherapeutics, Inc. per 2025 Jun 30 adalah 54.71 MM.
- Nilai kas dari aktivitas pendanaan untuk Bolt Biotherapeutics, Inc. per 2025 Jun 30 adalah 0.04 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -51.36 | 54.71 | 0.04 |
2025-03-31 | -57.90 | 61.92 | 0.11 |
2024-12-31 | -61.29 | 57.58 | 0.11 |
2024-09-30 | -61.12 | 61.15 | 0.18 |
2024-06-30 | -63.91 | 56.67 | 0.18 |
2024-03-31 | -62.88 | 52.25 | 0.25 |
2023-12-31 | -69.53 | 71.04 | 0.25 |
2023-09-30 | -73.21 | 71.66 | 0.29 |
2023-06-30 | -69.91 | 60.46 | 0.29 |
2023-03-31 | -75.59 | 46.01 | 0.40 |
2022-12-31 | -76.50 | 57.86 | 0.50 |
2022-09-30 | -76.35 | 62.46 | 0.85 |
2022-06-30 | -81.62 | 44.90 | 1.04 |
2022-03-31 | -64.82 | -0.83 | 14.20 |
2021-12-31 | -57.07 | -232.20 | 311.11 |
2021-09-30 | -52.16 | -251.53 | 309.55 |
2021-06-30 | -45.95 | -248.51 | 308.44 |
2021-03-31 | -54.23 | -197.50 | 336.58 |
2020-12-31 | -47.31 | -20.59 | 39.60 |
2020-09-30 | -40.68 | -22.36 | 40.69 |
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah 0.24.
- p/tbv untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah 0.24.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 0.24 | 0.24 | |
2025-03-31 | 0.28 | 0.28 | |
2024-12-31 | 0.30 | 0.30 | |
2024-09-30 | -0.36 | 0.28 | 0.28 |
2024-06-30 | -0.45 | 0.27 | 0.27 |
2024-03-31 | -0.77 | 0.47 | 0.47 |
2023-12-31 | -0.60 | 0.33 | 0.33 |
2023-09-30 | -0.51 | 0.28 | 0.28 |
2023-06-30 | -0.62 | 0.32 | 0.32 |
2023-03-31 | -0.59 | 0.31 | |
2022-12-31 | 0.26 | 0.26 | |
2022-09-30 | 0.27 | 0.27 | |
2022-06-30 | -0.78 | 0.33 | 0.33 |
2022-03-31 | -1.02 | 0.40 | 0.40 |
2021-12-31 | -1.79 | 0.67 | 0.67 |
2021-09-30 | -5.27 | 1.59 | 1.59 |
2021-06-30 | |||
2021-03-31 | -0.79 | 0.20 | 0.20 |
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -23.73.
- EBIT (3 tahun) / EV untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -25.76.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -23.73 | -25.76 |
2025-03-31 | -6.94 | -7.61 |
2024-12-31 | -5.23 | -5.95 |
2024-09-30 | -3.77 | -4.42 |
2024-06-30 | -2.61 | -3.34 |
2024-03-31 | -1.63 | -2.00 |
2023-12-31 | -2.12 | -2.66 |
2023-09-30 | -3.00 | -3.42 |
2023-06-30 | -2.30 | -2.51 |
2023-03-31 | -2.04 | -2.03 |
2022-12-31 | -2.48 | -2.06 |
2022-09-30 | -2.90 | -2.37 |
2022-06-30 | -3.02 | -2.29 |
2022-03-31 | -1.34 | -0.94 |
2021-12-31 | -0.64 | -0.40 |
2021-09-30 | -0.22 | -0.10 |
2021-06-30 | ||
2021-03-31 | -0.80 | -0.42 |
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Efektivitas Manajemen
- roa untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -0.51.
- roe untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -0.74.
- roic untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -0.89.
- croic untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah 0.06.
- ocroic untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -0.81.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.51 | -0.74 | -0.89 | 0.06 | -0.81 |
2025-03-31 | -0.44 | -0.61 | -0.77 | -0.04 | -0.74 |
2024-12-31 | -0.41 | -0.58 | -0.72 | 0.00 | -0.68 |
2024-09-30 | -0.38 | -0.52 | -0.63 | -0.07 | -0.61 |
2024-06-30 | -0.31 | -0.40 | -0.51 | -0.08 | -0.51 |
2024-03-31 | -0.30 | -0.40 | -0.52 | 0.01 | -0.52 |
2023-12-31 | -0.29 | -0.38 | -0.48 | -0.01 | -0.49 |
2023-09-30 | -0.30 | -0.37 | -0.47 | -0.06 | -0.43 |
2023-06-30 | -0.31 | -0.39 | -0.47 | -0.06 | -0.43 |
2023-03-31 | -0.31 | -0.39 | -0.45 | -0.16 | -0.42 |
2022-12-31 | -0.29 | -0.35 | -0.45 | -0.06 | -0.36 |
2022-09-30 | -0.29 | -0.35 | -0.45 | -0.06 | -0.36 |
2022-06-30 | -0.28 | -0.33 | -0.42 | -0.15 | -0.35 |
2022-03-31 | -0.30 | -0.33 | -0.39 | -0.20 | -0.26 |
2021-12-31 | -2.20 | -4.01 | -0.36 | 0.08 | -0.17 |
2021-09-30 | -1.66 | -2.13 | -0.34 | 0.02 | -0.14 |
2021-06-30 | -1.31 | -1.66 | -0.28 | 0.04 | -0.14 |
2021-03-31 | -1.58 | -2.42 | -0.24 | 0.27 | -0.17 |
2020-12-31 | -1.25 | -1.92 | -1.67 | -0.78 | -1.30 |
2020-09-30 | -3.02 | -0.74 | -0.42 | -0.77 | |
2020-06-30 | -2.27 | -2.80 | -0.59 | 0.29 | -0.59 |
2020-03-31 | -2.01 | -2.49 | -0.77 | -0.20 | -0.72 |
Gross Margins
- marjin kotor untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -13.05.
- marjin bersih untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -17.41.
- marjin operasi untuk Bolt Biotherapeutics, Inc. pada 2025 Jun 30 adalah -17.39.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -13.05 | -17.41 | -17.39 |
2025-03-31 | -6.47 | -8.21 | -8.87 |
2024-12-31 | -5.35 | -6.66 | -7.40 |
2024-09-30 | -4.66 | -5.93 | -6.63 |
2024-06-30 | -4.60 | -5.57 | -6.61 |
2024-03-31 | -6.81 | -8.79 | -9.67 |
2023-12-31 | -7.62 | -9.90 | -10.76 |
2023-09-30 | -8.74 | -11.32 | -12.04 |
2023-06-30 | -9.29 | -11.32 | -12.04 |
2023-03-31 | 0.28 | -12.07 | -12.59 |
2022-12-31 | -15.32 | -19.74 | -19.97 |
2022-09-30 | -21.83 | -19.74 | -19.97 |
2022-06-30 | -37.55 | -27.96 | -28.14 |
2022-03-31 | 1.00 | -47.19 | -47.39 |
2021-12-31 | -89.47 | -78.25 | -73.64 |
2021-09-30 | -136.26 | -109.89 | |
2021-06-30 | |||
2021-03-31 | -710.90 | -1,142.52 | -878.55 |
2020-12-31 | -173.71 | -262.89 | -212.91 |
2020-09-30 | -110.24 | -131.94 | -141.10 |
2020-06-30 | -70.05 | -86.90 | -88.20 |
2020-03-31 | -72.04 | -88.20 | -89.69 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1641281 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |